MDXH MDXHEALTH

MDxHealth to Participate in Piper Sandler Healthcare Conference

MDxHealth to Participate in Piper Sandler Healthcare Conference

MDxHealth to Participate in Piper Sandler Healthcare Conference

IRVINE, CA – November 25, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City.

Piper Sandler 36th Annual Healthcare Conference

Fireside discussion: Wednesday, December 4, 3:00-3:25 pm ET

Webcast: 

A live webcast of the fireside chat will be accessible on the Investor page of mdxhealth’s website at . Replays will be available for up to 60 days following each event.

About mdxhealth®

Mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

LifeSci Advisors (IR & PR)

US:

NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.



EN
25/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MDXHEALTH

Guy Sips ... (+5)
  • Guy Sips
  • Jacob Mekhael
  • Michiel Declercq
  • Sharad Kumar S.P
  • Thomas Vranken
Thomas Vranken
  • Thomas Vranken

mdxhealth FIRST LOOK: FY24 highlights unlock path to EBITDA profitabil...

mdxhealth provides insight into key FY24 parameters, with revenues landing at $ 90m (KBCSe: $ 88.5m) and YE cash at $ 46.8m (KBCSe: $ 47.1m. Revenue guidance for FY25 is set at a narrow yet ambitious range of $ 108-110m, implying a 20-22% y/y increase. We believe that mdxhealth is well-positioned for growth in 2025 now that the commercial engine is firing on all cylinders, hence we maintain our $ 4.2 TP and Buy rating.

 PRESS RELEASE

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenu...

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance             MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, ...

 PRESS RELEASE

MDxHealth to Participate in Piper Sandler Healthcare Conference

MDxHealth to Participate in Piper Sandler Healthcare Conference MDxHealth to Participate in Piper Sandler Healthcare Conference IRVINE, CA – November 25, 2024 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced that Michael K. McGarrity, Chief Executive Officer, will participate in the Piper Sandler 36th Annual Healthcare Conference, which will take place between Dec 3-5, 2024, in New York City. Piper Sandler 36th Annual Healthcare ConferenceFireside discussion: Wednesday, December 4, 3:00-3:25 pm ETWebcast:  A live w...

Jacob Mekhael
  • Jacob Mekhael

mdxhealth FIRST LOOK: 3Q24 results come with upgraded FY24 guidance

mdxhealth reported 3Q24 revenue growth of 21% y/y, while management upgraded FY24 guidance to $ 87-89m (previously $ 85-87m) reflecting increased confidence in utilisation from healthcare providers. The goal to reach positive adjusted EBITDA by 1H25 remains on track, and now starts to come into view, while management guided for 20% topline growth for FY25. We reiterate our $ 4.2 TP and Buy rating.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch